CTRI/2022/07/044031已完成3 期
A multicentric randomized double blind parallel group two arm comparative phase III clinical study to evaluate the efficacy safety and tolerability of FDC of Azelnidipine 16 mg plus Telmisartan 40 mg Film Coated Tablets Versus FDC of Amlodipine 5 mg plus Telmisartan 40 mg tablets in subjects with stage 2 hypertension
Mascot Health Series PVT Ltd0 个研究点目标入组 220 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male or Female subjects of age 18 to 65 years (both inclusive).
- •2. Treatment-Naïve subjects diagnosed with Stage 2 Hypertension having mean SBP of >=160 to <=180 mmHg and mean DBP >=100 to <=110 mmHg (3 readings will be taken by validated automated blood pressure machine in sitting position, first reading will be taken after 15 min. rest and subsequent two readings will be recorded at the interval of 2 min. each).
- •3. Subjects with the ability to understand and provide a written informed consent form, which must have been obtained before the screening.
- •4. Subjects willing to comply with the protocol requirements.
排除标准
- •1.Suspected hypersensitivity to either the study medications or any of the formulation ingredients.
- •2.Subjects with a medical history of oncological conditions for the last 2 years.
- •3.Subjects with known cases of Epileptic seizures, clinical history of bipolar disorder i.e. who are taking lithium.
- •4. Patients suspected to be addicted to alcohol or drug abuse or with severe complications that would make the condition more complicated were assessed by the investigator.
- •5.Subject having any disease/ abnormalities as follow,
- •Cardiovascular system:
- •Subject with unstable angina pectoris, myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) surgery, and any clinically significant cardiac arrhythmias.
- •Subjects with known cases of Secondary or Malignant Hypertension.
- •Subjects with known cases of symptomatic congestive heart failure, severe aortic stenosis.
- •Endocrine system:
- •Subjects with abnormal Thyroid Function Test (TSH) [Normal range is 0.45 to 4.5 mIU/mL].
- •Subjects with Type 1 Diabetes Mellitus.
- •Subjects with Type 2 Diabetes Mellitus whose diabetes has not been stable and controlled for the previous three months and with an HbA1c value greater than 8%.
- •Renal system:
- •Subjects with hyperkalemia and hypokalemia as per blood biochemistry results at screening [Normal range 3.5 to 5.5 mEq/L.
- •Subjects with hyponatraemia as per blood biochemistry results at screening [Normal range 135 to 145 mEq/L].
- •Subjects with abnormal Renal Function Test (RFT) [Serum Creatinine Normal range 0.6 to 1.3 mg/dL] & [BUN Normal range 7 to 20 mg/dL].
- •Subjects with abnormal eGFR ( <60 mL/min/1.73 m2).
- •Subjects with known cases of bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant, or with only one functioning kidney.
- •Hepatic system:
- •Subjects with abnormal Liver Function Tests with values more than 2.5 times the upper limit of normal.
- •6.Female subjects who are pregnant or lactating or planning to become pregnant during the study period.
- •7.Females who are not ready to use acceptable contraceptive methods during study.
- •8.Concurrent participation in another clinical trial or any investigational therapy within 30 days before signing informed consent.
- •9.Currently taking prohibited concomitant medications(s) listed and inability/unwillingness to discontinue them for the entire study period.
- •10.Suspected inability or unwillingness to comply with the study procedures.
研究者
相似试验
已完成
2 期
Effect of Mupirocin ointment in bacterial skin infectionsCTRI/2022/02/040436Apex Laboratories Pvt Ltd200
尚未招募
3 期
Phase III clinical study evaluates the efficacy and safety of a combination eye drop containing Moxifloxacin/Nepafenac compared to Moxifloxacin/Ketorolac for patients with Inflammatory Ocular ConditionsCTRI/2024/08/071785Akums Drugs & Pharmaceuticals Limited
招募中
1 期
A multicenter randomized double-blind parallel controlled trial of chuangui clearing damp mixture in the treatment of primary hyperuricemiaITMCTR2100004310Affiliated Hospital of Qingdao University
尚未招募
1 期
A Multi-Centered Randomized Double-Blinded Parallel Controlled Clinical Study on Efficacy of Warming the Kidney, Invigorating the Spleen, Activating Blood and Removing Edema Method in the Treatment of Chronic Heart Failurechronic heart failureITMCTR2000003867Yueyang Hospital of Integrated Traditional Chinese and Western Medicine,Shanghai University of Traditional Chinese Medicine
已完成
3 期
A study to asses the efficacy and safety of TC-5214 as an adjunct therapy in patients with major depressive disorder.CTRI/2010/091/001410AstraZeneca2,236